Literature DB >> 22162556

Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer.

Morgan A Marks1, Philip E Castle, Mark Schiffman, Patti E Gravitt.   

Abstract

High-risk human papillomavirus (HR-HPV) testing is increasingly important. We therefore examined the impact on accuracy of repeated versus one-time testing, type-specific versus pooled detection, and assay analytic sensitivity. By using a nested case-control design from the ASCUS-LSIL Triage Study, we selected women with incident cervical intraepithelial neoplasia grade 2 or grade 3 (CIN2/3; n = 325) and a random sample of women with <CIN2 as controls (n = 401). HPV DNA status was assessed using hybrid capture 2 (HC2), a pooled test for 13 HR-HPV types, and the linear array (LA) and the line blot assay (LBA), two PCR-based HPV genotyping assays, at enrollment and the 6-month follow-up visit. The relative sensitivity and specificity for different permutations of multiple measurements were compared to a single measurement using marginal regression models. We found that repeat detection of any HR-HPV (by HC2, LA, or LBA) and of type-specific persistence (by LA or LBA) were significantly more specific but less sensitive than use of a single time point measurement of any HR-HPV. Sensitivity decreased and specificity increased further when testing intervals were increased from 12 to 24 months. Including detection of borderline carcinogenic/noncarcinogenic HPV types with HR-HPV types decreased specificity for repeat measures of HPV with no impact on sensitivity. Similar patterns were observed when we used a CIN3 end point. We conclude that assay performance for detecting incident CIN2/3 was affected by which types were included, the analytic sensitivity of the assay, and the testing interval. These trade-offs need to be considered when assessing the potential overall clinical utility of repeated testing for HR-HPV DNA to identify women at risk for CIN2/3.

Entities:  

Mesh:

Year:  2011        PMID: 22162556      PMCID: PMC3264159          DOI: 10.1128/JCM.05979-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

2.  A marginal regression modelling framework for evaluating medical diagnostic tests.

Authors:  W Leisenring; M S Pepe; G Longton
Journal:  Stat Med       Date:  1997-06-15       Impact factor: 2.373

3.  Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.

Authors:  Julia C Gage; Mark Schiffman; Diane Solomon; Cosette M Wheeler; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

4.  Natural history of cervicovaginal papillomavirus infection in young women.

Authors:  G Y Ho; R Bierman; L Beardsley; C J Chang; R D Burk
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

5.  ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants.

Authors:  M Schiffman; M E Adrianza
Journal:  Acta Cytol       Date:  2000 Sep-Oct       Impact factor: 2.319

6.  Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.

Authors:  Susanne K Kjaer; Adriaan J C van den Brule; Gerson Paull; Edith I Svare; Mark E Sherman; Birthe L Thomsen; Mette Suntum; Johannes E Bock; Paul A Poll; Chris J L M Meijer
Journal:  BMJ       Date:  2002-09-14

Review 7.  Findings to date from the ASCUS-LSIL Triage Study (ALTS).

Authors:  Mark Schiffman; Diane Solomon
Journal:  Arch Pathol Lab Med       Date:  2003-08       Impact factor: 5.534

8.  Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2003-06       Impact factor: 8.661

9.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

10.  Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Authors:  Mark E Sherman; Attila T Lorincz; David R Scott; Sholom Wacholder; Philip E Castle; Andrew G Glass; Iwona Mielzynska-Lohnas; Brenda B Rush; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

View more
  9 in total

1.  Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women.

Authors:  Shang-Ying Hu; Sabrina H Tsang; Feng Chen; Qin-Jing Pan; Wen-Hua Zhang; Ying Hong; Joshua N Sampson; Allan Hildesheim; Fang-Hui Zhao; Aimée R Kreimer
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 5.226

2.  Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.

Authors:  Shang-Ying Hu; Aimée R Kreimer; Carolina Porras; Diego Guillén; Mario Alfaro; Teresa M Darragh; Mark H Stoler; Luis F Villegas; Rebecca Ocampo; Ana Cecilia Rodriguez; Mark Schiffman; Sabrina H Tsang; Douglas R Lowy; John T Schiller; John Schussler; Wim Quint; Mitchell H Gail; Joshua N Sampson; Allan Hildesheim; Rolando Herrero
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

3.  Alcohol consumption and persistent infection of high-risk human papillomavirus.

Authors:  H Y Oh; M K Kim; S Seo; D O Lee; Y K Chung; M C Lim; J Kim; C W Lee; S Park
Journal:  Epidemiol Infect       Date:  2014-09-04       Impact factor: 4.434

4.  Synergistic effect of viral load and alcohol consumption on the risk of persistent high-risk human papillomavirus infection.

Authors:  Hea Young Oh; Sang-Soo Seo; Mi Kyung Kim; Dong Ock Lee; Youn Kyung Chung; Myong Cheol Lim; Joo-Young Kim; Chan Wha Lee; Sang-Yoon Park
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

5.  From Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice.

Authors:  Sin Hang Lee; Jessica S Vigliotti; Veronica S Vigliotti; William Jones
Journal:  Cancers (Basel)       Date:  2014-10-02       Impact factor: 6.639

6.  Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort.

Authors:  Jung Eun Lee; Sunghee Lee; Heetae Lee; Yun-Mi Song; Kayoung Lee; Min Ji Han; Joohon Sung; GwangPyo Ko
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

7.  Characterization of p16 and E6 HPV-related proteins in uterine cervix high-grade lesions of patients treated by conization with large loop excision.

Authors:  Maria Teresa Roncaglia; José Humberto T G Fregnani; Maricy Tacla; Silvana Gisele Pegorin DE Campos; Hélio Hehl Caiaffa; Alexandre Ab'saber; Eduardo Vieira DA Motta; Venâncio Avancini Ferreira Alves; Edmund C Baracat; Adhemar Longatto Filho
Journal:  Oncol Lett       Date:  2013-05-20       Impact factor: 2.967

8.  Vaginal microbiota diversity and paucity of Lactobacillus species are associated with persistent hrHPV infection in HIV negative but not in HIV positive women.

Authors:  Eileen O Dareng; Bing Ma; Sally N Adebamowo; Ayotunde Famooto; Jacques Ravel; Paul P Pharoah; Clement A Adebamowo
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

9.  Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review.

Authors:  Jesper Bonde; Fabio Bottari; Anna D Iacobone; Clementina E Cocuzza; Maria-Teresa Sandri; Fabrizio Bogliatto; Khalid S Khan; Ditte M Ejegod; Devin S Gary; Jeffrey C Andrews
Journal:  J Low Genit Tract Dis       Date:  2021-01-01       Impact factor: 3.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.